Every material Form 8-K Medpace has filed with the SEC since March 29, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medpace reported third quarter 2026 revenue of $716.0 million, up 8.5%, and GAAP diluted earnings of $4.84 per share, up from $3.86 a year earlier. The company also replaced its prior buyback, which had $527.0 million remaining, with a new authorization of up to $1.0 billion of common stock through December 31, 2028, funded from cash on hand.
Q3 2026 revenue $716.0 million, up 8.5% from $659.9 million; net new business awards $873.4 million, up 10.6%
Q3 2026 GAAP net income $137.5 million ($4.84 per diluted share) vs. $111.1 million ($3.86) a year earlier; EBITDA $172.1 million, up 16.0%
New repurchase authorization of up to $1.0 billion through December 31, 2028, effective October 20, 2026, replacing the prior authorization with $527.0 million remaining
The filing gives 2026 full-year guidance of $2.835 billion to $2.855 billion in revenue and $17.97 to $18.32 in diluted EPS, with no prior guidance included for comparison
Medpace reported second quarter 2026 revenue of $707.3 million, up 17.2% from a year earlier, and GAAP net income of $121.4 million, or $4.25 per diluted share, compared with $3.10 a year earlier. The company also forecast full-year 2026 revenue of $2.805 billion to $2.885 billion and diluted EPS of $17.25 to $17.95.
Q2 2026 revenue $707.3 million, up 17.2% from $603.3 million in Q2 2025
Q2 2026 GAAP net income $121.4 million ($4.25 diluted EPS) vs. $90.3 million ($3.10) a year earlier
Q2 2026 net new business awards $795.7 million, up 28.2%; book-to-bill ratio 1.13x
Full-year 2026 guidance: revenue $2.805 billion to $2.885 billion; GAAP net income $494.0 million to $514.0 million
Medpace Holdings appointed Brad W. Hansman, age 43, as Executive Vice President, Operations, effective June 1, 2026. He will perform the functions of the company's principal operating officer alongside Susan E. Burwig, the current Executive Vice President, Operations. The filing discloses a $492,250 base salary and incentive eligibility, which is a routine leadership change for shareholders.
Brad W. Hansman, age 43, appointed Executive Vice President, Operations, effective June 1, 2026
Hansman will share principal operating officer duties with Susan E. Burwig
Annual base salary of $492,250, plus eligibility for short-term incentive and long-term equity plans
Medpace reported first quarter 2026 revenue of $706.6 million, up 26.5% from a year earlier, and GAAP diluted earnings of $4.28 per share, up from $3.67. Net income margin fell to 17.5% from 20.5%, and the company set full-year 2026 revenue guidance of $2.755 billion to $2.855 billion. President Jesse Geiger also notified the company he will retire effective May 31, 2026, and CEO August Troendle will assume the president role until a successor is appointed.
Q1 2026 revenue $706.6 million, up 26.5% from $558.6 million; GAAP net income $123.9 million, or $4.28 per diluted share, versus $114.6 million, or $3.67, a year earlier
Q1 2026 EBITDA $149.4 million, up 25.9%; net income margin 17.5% versus 20.5% in Q1 2025
2026 guidance: revenue $2.755 billion to $2.855 billion; GAAP diluted EPS $16.68 to $17.50
Jesse Geiger to retire as President effective May 31, 2026; not due to any disagreement with the company
Medpace reported fourth-quarter and full-year 2025 results on February 9, 2026. Revenue and GAAP earnings per diluted share both rose from the prior-year periods, and the company gave a 2026 forecast for revenue, GAAP net income and EBITDA, with the forecast implying slower revenue growth than in 2025.
Q4 2025 revenue was $708.5 million, up 32.0% from $536.6 million; GAAP diluted EPS was $4.67 versus $3.67.
Full-year 2025 revenue was $2.53 billion, up 20.0%; GAAP diluted EPS was $15.28 versus $12.63.
2026 guidance: revenue of $2.755 billion to $2.855 billion (8.9% to 12.8% growth) and GAAP diluted EPS of $16.68 to $17.50.
No share repurchases in Q4 2025; $821.7 million remained under the buyback program at December 31, 2025.
Medpace reported third-quarter 2025 revenue of $659.9 million, up 23.7% from a year earlier, and GAAP diluted earnings per share of $3.86, up from $3.01. Net income margin slipped to 16.8% from 18.1%, and the filing gives 2025 revenue and EPS forecasts but no prior forecast to compare them with.
Q3 2025 revenue $659.9 million, up 23.7% from $533.3 million; EBITDA $148.4 million, up 24.9%
Q3 net new business awards $789.6 million, up 47.9%, for a book-to-bill ratio of 1.20x
Q3 GAAP net income $111.1 million, or $3.86 per diluted share, vs $96.4 million, or $3.01, a year earlier
2025 guidance: revenue $2.480 billion to $2.530 billion and GAAP diluted EPS $14.60 to $14.86
Medpace reported second-quarter 2025 revenue of $603.3 million, up 14.2% from a year earlier, and GAAP diluted earnings of $3.10 per share, up from $2.75. Net income margin fell to 15.0% from 16.7%, and backlog declined 1.8% to $2,873.6 million, while the company repurchased $518.5 million of its stock in the quarter and issued full-year 2025 guidance.
Q2 2025 revenue $603.3 million, up 14.2% from $528.1 million; GAAP net income $90.3 million, or $3.10 per diluted share, vs. $2.75 a year earlier
Full-year 2025 guidance: revenue $2.420 billion to $2.520 billion; GAAP net income $405.0 million to $428.0 million; diluted EPS $13.76 to $14.53
Q2 share repurchases of 1,754,264 shares for $518.5 million; $826.3 million remained under the program as of June 30, 2025
Amendment No. 9 to the PNC Bank unsecured credit facility, dated July 17, 2025, sets line-of-credit borrowing of up to $10 million
At its May 16, 2025 annual meeting, Medpace stockholders approved the Amended 2016 Incentive Award Plan, which extends the plan's expiration date to February 6, 2035 without adding authorized shares. Stockholders also elected August J. Troendle and Dani S. Zander as Class III directors, ratified Deloitte & Touche LLP as auditor for 2025, and approved an advisory say-on-pay vote and a non-binding simple majority voting proposal.
Amended 2016 Plan extends expiration to February 6, 2035 and does not increase authorized shares; approved 25,567,981 for, 702,406 against
Troendle received 21,156,998 votes for and 5,128,383 withheld; Zander received 25,858,694 for and 426,687 withheld
Advisory say-on-pay approved with 24,918,234 for and 1,340,033 against
Non-binding simple majority voting proposal approved with 18,210,462 for and 8,021,457 against
Medpace reported first-quarter 2025 revenue of $558.6 million and GAAP diluted EPS of $3.67, both up from the prior-year quarter, and issued 2025 guidance of $2.140 billion to $2.240 billion in revenue and $12.26 to $13.04 in diluted EPS. Its board also raised the stock repurchase program by $1.0 billion on April 17, 2025, and the company amended its $600 million unsecured credit facility with PNC Bank.
Q1 2025 revenue was $558.6 million, up 9.3% from $511.0 million; GAAP net income was $114.6 million, or $3.67 per diluted share, versus $3.20 a year earlier.
Net new business awards fell 18.8% to $500.0 million, giving a 0.90x book-to-bill ratio; backlog decreased 2.1% to $2,846.0 million.
Board approved a $1.0 billion increase to the stock repurchase program on April 17, 2025; $344.8 million remained under the program at March 31, 2025.
Full-year 2025 guidance: revenue of $2.140 billion to $2.240 billion and GAAP diluted EPS of $12.26 to $13.04.
Medpace Holdings and subsidiaries signed Amendment No. 7 to its unsecured credit facility with PNC Bank, National Association, on March 28, 2025. The amendment extends the expiration date of the revolving credit note to March 31, 2026, keeping the company's existing borrowing arrangement in place for another year.
Agreement dated March 28, 2025 with PNC Bank, National Association, under the unsecured credit facility
Amendment No. 7 extends the revolving credit note expiration date to March 31, 2026
Medpace, Inc. is borrower and Medpace IntermediateCo, Inc. is guarantor; full text filed as Exhibit 10.1
Medpace reported fourth-quarter 2024 revenue of $536.6 million, up 7.7%, and GAAP diluted earnings of $3.67 per share, up from $2.46 a year earlier. The board also approved a $600 million increase to the stock repurchase program, and the company forecast 2025 revenue of $2.110 billion to $2.210 billion, growth of 0.0% to 4.8%, for shareholders to weigh against slower new business awards.
Q4 2024 revenue was $536.6 million, up 7.7% from $498.4 million; GAAP net income was $117.0 million.
Q4 2024 net new business awards fell 13.8% to $529.7 million, for a net book-to-bill ratio of 0.99x.
2025 guidance: revenue of $2.110 billion to $2.210 billion and GAAP diluted EPS of $11.93 to $12.69.
On February 6, 2025, the board approved a $600 million increase to the stock repurchase program.
Medpace reported third-quarter 2024 revenue of $533.3 million, up 8.3% from a year earlier, and GAAP net income of $96.4 million, or $3.01 per diluted share, versus $2.22 in the prior-year quarter. Net new business awards fell 12.7% to $533.7 million, but the net book-to-bill ratio was 1.00x and backlog rose 8.8% to $2,927.4 million. The company forecast full-year 2024 revenue of $2.090 billion to $2.130 billion and GAAP diluted EPS of $11.71 to $12.09.
Q3 2024 revenue was $533.3 million, up 8.3% from $492.5 million; EBITDA rose 31.7% to $118.8 million.
Q3 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus $2.22 a year earlier.
Net new business awards were $533.7 million, down 12.7% from $611.5 million; backlog was $2,927.4 million as of September 30, 2024.
2024 guidance: revenue of $2.090 billion to $2.130 billion and GAAP diluted EPS of $11.71 to $12.09.
Medpace reported second quarter 2024 results on July 22, 2024, with revenue up 14.6% year over year and GAAP net income of $88.4 million, or $2.75 per diluted share, versus $1.93 a year earlier. The company also gave full-year 2024 guidance of $2.125 billion to $2.175 billion in revenue and $11.24 to $11.93 in diluted EPS, but net new business awards fell 4.1% in the quarter.
Q2 2024 revenue was $528.1 million, up 14.6% from $460.9 million; EBITDA rose 34.2% to $112.3 million.
Q2 2024 net new business awards were $551.0 million, down 4.1% from $574.8 million, for a net book-to-bill ratio of 1.04x.
2024 guidance: revenue of $2.125 billion to $2.175 billion, GAAP net income of $361.0 million to $383.0 million, and diluted EPS of $11.24 to $11.93.
No share repurchases were made in Q2 2024; $308.8 million remained under the authorized program as of June 30, 2024.
Medpace director Ashley M. Keating resigned from the Board effective June 30, 2024, stating no disagreement with the company. The Board appointed Dr. Dani S. Zander to fill the resulting Class III vacancy effective July 1, 2024, and to the Nominating and Governance Committee.
Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement on operations, policies or practices cited.
Dr. Dani S. Zander was elected to the Class III vacancy effective July 1, 2024, serving until the 2025 Annual Meeting of Stockholders.
Dr. Zander joined the Nominating and Governance Committee effective July 1, 2024.
Dr. Zander received a director equity award of an option to purchase 824 shares at the July 1, 2024 closing price, with a seven-year term.
Medpace reported first-quarter 2024 revenue of $511.0 million, up 17.7% from a year earlier, and GAAP net income of $102.6 million, or $3.20 per diluted share, versus $2.27 a year earlier. The company also forecast full-year 2024 revenue of $2.150 billion to $2.200 billion and GAAP diluted EPS of $10.79 to $11.47, and reported no share repurchases in the quarter.
Q1 2024 revenue $511.0 million, up 17.7% from $434.1 million; backlog rose 18.2% to $2,907.1 million.
Q1 2024 GAAP net income $102.6 million, or $3.20 per diluted share, vs. $72.9 million, or $2.27, in Q1 2023; EBITDA rose 24.6% to $115.7 million.
2024 guidance: revenue $2.150 billion to $2.200 billion; GAAP net income $347.0 million to $369.0 million.
No share repurchases in Q1 2024; $308.8 million remained under the authorized program at March 31, 2024.
Medpace Holdings and its subsidiaries signed Amendment No. 6 to the loan documents for its unsecured credit facility with PNC Bank, National Association, on March 28, 2024. The amendment sets the aggregate principal that may be borrowed under the line of credit at up to $10 million and extends the revolving credit note's expiration date to March 31, 2025. The filing does not state the prior borrowing limit, and the change is administrative in nature.
Amendment No. 6 to Loan Documents dated March 28, 2024, with PNC Bank, National Association
Aggregate principal borrowable under the line of credit set at up to $10 million
Revolving credit note expiration extended to March 31, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Medpace filing is on SEC EDGAR ↗. 8-K briefs of other companies →